{"id":"NCT00357097","sponsor":"GlaxoSmithKline","briefTitle":"The Effects Of Ropinirole On Mood Or Mild Depression In Patients With Moderate To Severe Restless Legs Syndrome","officialTitle":"A Multicenter 3:1-randomized Placebo-controlled Double-blind Phase IIIb Study on the Effects of Ropinirole on Mood/(Subclinical) Depression in the Therapy of Patients With Moderate to Severe Idiopathic RLS in Germany","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2006-06","primaryCompletion":"2007-12","completion":"2007-12","firstPosted":"2006-07-27","resultsPosted":"2009-09-16","lastUpdate":"2012-06-07"},"enrollment":240,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Restless Legs Syndrome","Moderate to Severe Idiopathic Restless Legs Syndrome (RLS)"],"interventions":[{"type":"DRUG","name":"Ropinirole","otherNames":[]}],"arms":[],"summary":"Ropinirole has shown to improve mood in depressed patients as well as to improve the symptoms of Restless Legs Syndrome. Up to 40% of RLS patients suffer from mild depression, therefore it would be important for decisions no therapy to know whether a drug could improve both depressive and RLS symptoms.","primaryOutcome":{"measure":"Average Change of the MADRS (Montgomery-Asberg Depression Rating Scale) Total Score From Baseline to Final Visit After 12 Weeks of Treatment","timeFrame":"Baseline and Week 12","effectByArm":[{"arm":"Ropinirole","deltaMin":-10.1,"sd":7.3},{"arm":"Placebo","deltaMin":-6.5,"sd":7.6}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":15},"locations":{"siteCount":50,"countries":["Germany"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":4},"commonTop":["Nausea","Headache","Fatigue","Dizziness","Vomiting"]}}